Compare CCEP & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCEP | IQV |
|---|---|---|
| Founded | 1986 | 1982 |
| Country | United Kingdom | United States |
| Employees | 41000 | 93000 |
| Industry | Beverages (Production/Distribution) | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.4B | 43.1B |
| IPO Year | 2015 | 2013 |
| Metric | CCEP | IQV |
|---|---|---|
| Price | $100.71 | $260.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 22 |
| Target Price | $109.20 | ★ $286.79 |
| AVG Volume (30 Days) | ★ 1.4M | 1.2M |
| Earning Date | 08-04-2026 | 10-27-2026 |
| Dividend Yield | ★ 2.35% | N/A |
| EPS Growth | N/A | ★ 4.67 |
| EPS | N/A | ★ 1.61 |
| Revenue | N/A | ★ $9,739,000,000.00 |
| Revenue This Year | $3.29 | $6.77 |
| Revenue Next Year | $3.86 | $6.06 |
| P/E Ratio | ★ $20.93 | $166.22 |
| Revenue Growth | N/A | ★ 41.60 |
| 52 Week Low | $84.66 | $154.50 |
| 52 Week High | $113.67 | $277.40 |
| Indicator | CCEP | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 41.59 | 56.72 |
| Support Level | $99.00 | $252.53 |
| Resistance Level | $109.54 | $274.60 |
| Average True Range (ATR) | 1.74 | 6.32 |
| MACD | 0.05 | -1.26 |
| Stochastic Oscillator | 27.58 | 34.11 |
CCEP is the second-largest bottling partner in the Coca-Cola system by volume, behind Coca-Cola Femsa, and primarily operates in developed Europe, Australasia, and Southeast Asia. In 2025, CCEP sold 3.9 billion unit cases of beverages, which we estimate equates to roughly 9% of the global Coke system volume.TCCC owns 19% of the equity of CCEP, Olive Partners, a holding company of bottling operations, owns a further 36%, and the remaining 45% is free float.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.